<DOC>
	<DOCNO>NCT01512407</DOCNO>
	<brief_summary>We hypothesise use transarterial chemoembolisation ( TACE ) liver resection patient hepatocellular carcinoma eradicate residual cancer cell liver thus improve survival . The aim study compare survival patient undergo liver resection plus post-operative TACE versus liver resection alone .</brief_summary>
	<brief_title>RCT Adjuvant TACE After Hepatectomy HCC</brief_title>
	<detailed_description>Liver resection mainstay curative treatment hepatocellular carcinoma ( HCC ) . However , recurrence common surgery occur liver . Transarterial chemoembolisation ( TACE ) effective palliative treatment HCC . It involve infusion chemotherapeutic agent admix iodised oil follow embolisation hepatic arterial flow use small particle . This procedures allow application small dose chemotherapy concentrate liver thus well tolerate minimal side effect . We conduct randomise controlled trial evaluate efficacy use TACE hepatectomy HCC patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>HCC patient receive curative hepatectomy negative resection margin Age 18 70 ChildPugh class A ASA class I III ECOG performance status Grade 0 1 Patients receive concomitant local ablation previous TACE Main portal vein tumour thrombus extraction hepatectomy Tumour arise caudate lobe Presence extrahepatic disease Very early HCC solitary tumour size &lt; 2cm Impaired liver function either clinically detect ascites , hepatic encephalopathy , serum albumin &lt; 25g/L bilirubin &gt; 50micromol/L Renal impairment creatinine &gt; 200micromol/L Severe concurrent medical illness persist &gt; 6 week hepatectomy History cancer Hepatic artery anomaly make TACE possible Allergy cisplatin lipiodol Pregnant woman Informed consent available</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Randomised control trial</keyword>
	<keyword>Transarterial chemoembolisation</keyword>
</DOC>